Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab with SOX and/or Apatinib in Locally Advanced Gastric or GEJ Cancer
NCT04792515Phase 2Unknown
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- Jan 2021
- Primary completion
- Jun 2022
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in gastric cancer (GC), gastroesophageal junction adenocarcinoma, sponsored by First Affiliated Hospital of Xi'an Jiaotong University. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT04792515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04792515.